Page last updated: 2024-08-04 07:52:04
ly2605541
Description
LY2605541: an insulin lispro analog with polyethylene glycol covalently attached to lysine B28 via a urethane linkage [MeSH]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 168324442 |
| MeSH ID | M0592875 |
Synonyms (1)
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 7 (63.64%) | 5.53% |
| Reviews | 2 (18.18%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 2 (18.18%) | 84.16% |
Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.Diabetes, obesity & metabolism, , Volume: 16, Issue:4, 2014
PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue.Diabetes, obesity & metabolism, , Volume: 16, Issue:5, 2014
Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.Diabetes, obesity & metabolism, , Volume: 16, Issue:4, 2014
The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?Expert opinion on biological therapy, , Volume: 14, Issue:6, 2014
Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.Diabetes care, , Volume: 37, Issue:3, 2014
Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.Diabetes, obesity & metabolism, , Volume: 16, Issue:4, 2014
A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.Diabetes technology & therapeutics, , Volume: 16, Issue:8, 2014
PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue.Diabetes, obesity & metabolism, , Volume: 16, Issue:5, 2014
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.Diabetes care, , Volume: 35, Issue:11, 2012
Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.Diabetes, obesity & metabolism, , Volume: 16, Issue:4, 2014
Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.Diabetes care, , Volume: 37, Issue:3, 2014
Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.Diabetes, obesity & metabolism, , Volume: 16, Issue:4, 2014
A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.Diabetes technology & therapeutics, , Volume: 16, Issue:8, 2014
PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue.Diabetes, obesity & metabolism, , Volume: 16, Issue:5, 2014
Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.Diabetes, obesity & metabolism, , Volume: 16, Issue:4, 2014
PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue.Diabetes, obesity & metabolism, , Volume: 16, Issue:5, 2014
Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.Diabetes, obesity & metabolism, , Volume: 16, Issue:4, 2014
A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.Diabetes technology & therapeutics, , Volume: 16, Issue:8, 2014
Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.Diabetes care, , Volume: 37, Issue:3, 2014
The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?Expert opinion on biological therapy, , Volume: 14, Issue:6, 2014
Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.Diabetes, obesity & metabolism, , Volume: 16, Issue:4, 2014
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.Diabetes care, , Volume: 35, Issue:11, 2012
Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.Diabetes, obesity & metabolism, , Volume: 16, Issue:4, 2014
Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.Diabetes, obesity & metabolism, , Volume: 16, Issue:4, 2014
A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.Diabetes technology & therapeutics, , Volume: 16, Issue:8, 2014
Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.Diabetes care, , Volume: 37, Issue:3, 2014
Pharmacokinetics (3)
| Article | Year |
|---|
Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function.
Clinical pharmacology in drug development, , Volume: 5, Issue:3 | 2016 |
Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Journal of clinical pharmacology, , Volume: 54, Issue:7 | 2014 |
Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.
Diabetes, obesity & metabolism, , Volume: 16, Issue:4 | 2014 |
Bioavailability (1)
Dosage (2)